Conventus Orthopaedics, Inc., a medical device company dedicated to revolutionizing fracture treatment, today announced that it has acquired all assets of IntraFuse, LLC. IntraFuse has developed proprietary intramedullary implants for the minimally invasive repair of fractures, including fibula fractures. This acquisition marks the first step of Conventus’ intended expansion into lower extremity orthopaedics.
IntraFuse’s FlexThread™ implants are FDA cleared and protected by 5 issued patents and 8 pending patents.
“Conventus is enthusiastic to expand beyond our innovative CAGE technology portfolio,” said Rick Epstein, CEO of Conventus Orthopaedics. “The FlexThread technology offers unique, minimally invasive and easy to use intramedullary products for small bone fractures. These products complement our intramedullary CAGE products for large bone peri-articular fractures. With the backing of our lead investor, Deerfield Management, this acquisition is a first step of what will be an aggressive transformation from a single product company into a formidable orthopaedic supplier. I have high expectations for continued business development activity coupled with development of proprietary devices.”
“The IntraFuse acquisition shows our commitment to support Conventus in execution of strategic portfolio development,” said Andrew ElBardissi, MD, Partner at Deerfield Management. “We are excited to see their portfolio strengthened with the FlexThread technology and look forward to Conventus’ continued expansion through acquisitions and internal development.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Transaction details were not disclosed.
Source: PR Newswire
